Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouchi, Motoshi, Oba, Kenzo, Kaku, Kohei, Suganami, Hideki, Yoshida, Akihiro, Fukunaka, Yasunori, Jutabha, Promsuk, Morita, Asuka, Otani, Naoyuki, Hayashi, Keitaro, Fujita, Tomoe, Suzuki, Tatsuya, Yasutake, Masahiro, Anzai, Naohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887894/
https://www.ncbi.nlm.nih.gov/pubmed/29171930
http://dx.doi.org/10.1111/dom.13170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887894/
https://www.ncbi.nlm.nih.gov/pubmed/29171930
http://dx.doi.org/10.1111/dom.13170

Ejemplares similares